Method for treating leishmaniasis using methyl-beta-cyclodextrin

Abstract

The present invention relates to a composition useful for the treatment of leishmaniasis said composition comprising pharmaceutically effective amount of methyl-beta-cyclodextrin, optionally along with other anti-leishmanial agent(s) and/or pharmaceutically acceptable additives, and a method thereof, wherein the said method reduces the cholesterol levels of the plasma membrane of the infected host cells by about 50%.

1 . A method of treating leishmaniasis said method consisting of step of administering a composition comprising pharmaceutically effective amount of methyl-beta-cyclodextrin optionally along with other anti-leishmanial agent(s) and/or pharmaceutically acceptable additives, to a subject in need thereof.  
     
     
         2 . A method as claimed in  claim 1 , wherein the said method reduces the cholesterol levels of the plasma membrane of the infected host cells by about 50%.  
     
     
         3 . A method as claimed in  claim 1 , wherein said additives are selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and/or pharmaceutically acceptable carrier, excipient, diluent, or solvent.  
     
     
         4 . A method as claimed in  claim 1 , wherein the composition is administered orally, inhaled, or implanted.  
     
     
         5 . A method as claimed in  claim 1 , wherein, the composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.  
     
     
         6 . A method as claimed in  claim 1 , wherein the subject is useful animals or human beings.  
     
     
         7 . A method as claimed in  claim 1 , wherein said method shows no adverse effect on subject.  
     
     
         8 . A method as claimed in  claim 1 , wherein the dosage of the methyl-beta-cyclodextrin is ranging between 20 to 500 mg/kg body weight of the subject  
     
     
         9 . A method as claimed in  claim 1 , wherein the ratio of methyl-beta-cyclodextrin to additives is ranging between 1:10 to 10:1.  
     
     
         10 . A method as claimed in  claim 2 , wherein the said method shows no effect on the other forms of lipids.  
     
     
         11 . A method as claimed in  claim 1 , wherein the anti-leishmanial effect increases with an increase in the amount of methyl-beta-cyclodextrin administered to a subject.  
     
     
         12 . A method as claimed in  claim 1 , wherein the anti-leishmanial effect increases with an increase in the time duration of exposure of methyl-beta-cyclodextrin to a subject.  
     
     
         13 . A composition useful for the treatment of leishmaniasis said composition comprising pharmaceutically effective amount of methyl-beta-cyclodextrin, optionally along with other anti-leishmanial agent(s) and/or pharmaceutically acceptable additives.  
     
     
         14 . A composition as claimed in  claim 13 , wherein the concentration of methyl-beta-cyclodextrin is ranging between 20 to 500 mg/kg body weight of the subject.  
     
     
         15 . A composition as claimed in  claim 13 , wherein the ratio of methyl-beta-cyclodextrin to additives is ranging between 1:10 to 10:1.  
     
     
         16 . A composition as claimed in  claim 13 , wherein said additives are selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and/or pharmaceutically acceptable carrier, excipient, diluent, or solvent.  
     
     
         17 . A composition as claimed in  claim 13 , wherein the composition is administered orally, inhaled, or implanted.  
     
     
         18 . A composition as claimed in  claim 13 , wherein, the composition for the oral route is in form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, and/or beads.